查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1836815

胜肽治療市場按產品類型、合成技術、給藥途徑、應用和最終用戶分類－2025-2032 年全球預測

Peptide Therapeutics Market by Product Type, Synthesis Technique, Route Of Administration, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年胜肽治療市場將成長至 692.6 億美元，複合年成長率為 8.61%。

主要市場統計數據
基準年2024年 357.6億美元
預計2025年 388.8億美元
預測年份：2032年 692.6億美元
複合年成長率（%） 8.61%

胜肽療法的策略入門，涵蓋科學進步、轉化推動因素和相關人員對臨床發展的影響

胜肽療法已從實驗室的奇思妙想發展成為連接小分子和大型生技藥品的關鍵治療方法，重塑了藥物研發和臨床治療的軌跡。過去十年，胜肽設計、穩定性工程和標靶遞送領域的不斷進步，擴大了胜肽在代謝、感染疾病領域的治療範圍。本篇導論將胜肽療法置於更廣泛的生物製藥創新領域，並重點介紹了那些揭示新作用機制和臨床效用的轉化里程碑。

將胜肽科學轉化為可行的療法需要化學、合成技術和製劑科學領域的協同進步。固相合成、重組生產和新型偶聯策略的改進，提高了胜肽資產的化學多樣性和可製造性。同時，監管機構完善了評估胜肽相關品質屬性的框架，減少了開發路徑中的模糊性，並支持了申辦者和監管機構之間更可預測的互動。因此，研究機構、小型生物技術公司和成熟的製藥公司正在擴大協調資源，以加速其胜肽產品線的開發。

展望未來，新一代穩定化學製劑、增強型遞送平台和計算設計工具的引進，可望降低臨床應用的門檻。因此，相關人員必須採取整合策略，協調藥物的發現、開發和生產，以充分利用該治療方法的獨特治療潛力，同時應對監管、供應鏈和支付方等複雜因素。

為什麼運算設計、藥物輸送創新和協作平台策略從根本上改變了胜肽類藥物開發的優先順序和軌跡

現代胜肽類藥物的格局正被幾項變革性變革重塑，這些變革正在全面調整研究重點和商業策略。首先，計算胜肽設計和人工智慧驅動的序列最佳化縮短了設計迭代周期，使研究團隊能夠優先考慮目標結合度和藥物動力學特徵更佳的候選化合物。其次，製劑和給藥方面的突破性進展，包括穩定化學和新型輔料系統，擴展了口服和長效腸外肽類藥物的可行性，提高了患者依從性和門診給藥的便利性。

同時，不斷發展的臨床需求正在推動胜肽應用的多樣化。抗菌肽正被重新發現，成為對抗抗生素抗藥性的工具，而細胞穿透胜肽則為細胞內靶向和寡核苷酸遞送開闢了新的途徑。由於抗原設計和佐劑系統的改進，胜肽疫苗被定位為傳統疫苗平台的補充或替代方法。這些科學進步透過更靈活的共同研究模式進一步發展，這些模式將學術實驗室、專業合約開發公司和綜合生物製藥團隊連接起來，加速了轉化研究的勢頭。

同時，製造創新正在重塑生產的經濟性和可擴展性。重組生產方法和序列最佳化的合成方法正在減少大分子胜肽和胜肽偶聯物的技術限制。因此，開發商的策略重點正從單一資產最佳化轉向能夠支援模組化產品線擴展和快速商業化路徑的平台能力。這些轉變共同為肽療法創造了一個更具活力、跨學科的生態系統。

2025 年美國關稅格局對胜肽供應鏈、籌資策略和臨床製造連續性的營運影響

美國2025年實施的關稅調整，為胜肽供應鏈和生產策略帶來了新的複雜性。其累積影響不僅限於直接成本影響，還影響採購決策、採購週期以及生產和品管活動的地理位置。依賴跨境原料採購、專業合成服務和契約製造關係的組織不得不重新評估其供應商矩陣和庫存政策，以保持臨床和商業生產的連續性。

此外，海關環境正在加速關於在地化與多元化的策略對話。一些公司正在考慮將關鍵的胜肽合成和灌裝生產能力整合到更靠近其生產基地的地方，以減輕進口關稅和邊境相關延誤的影響；而另一些公司則正在與國際供應商協商長期契約，以確保價格穩定和產品供應。法律和合規團隊正在同時考慮分類代碼和供應鏈可追溯性措施，以確保準確的海關處理，並在適用的情況下確定潛在的豁免。這些營運調整迫使申辦方重新評估臨床試驗材料的生產時間表，並將海關風險納入其採購管治。

為了應對這項挑戰，產業相關人員正在採取各種緩解策略，包括雙重採購安排、投資國內產能以及增強庫存韌性。因此，開發團隊擴大將關稅情景納入其專案風險暫存器和應急計劃中，從而使財務計劃與營運實際情況保持一致，並在應對更加分散的貿易格局的同時，維持患者可及性承諾。

詳細洞察細分市場，展示開發路徑如何因產品類型、合成方法、給藥途徑、治療用途和最終用戶而異

基於細分市場的洞察揭示了治療和技術選擇如何影響胜肽類藥物的開發重點和商業性定位。根據產品類型，開發人員將其產品組合分為抗菌肽、細胞滲透性肽、肽激素和胜肽疫苗，每種產品都有各自的標靶檢驗、安全性和監管考量。抗菌肽需要嚴格的抗藥性分析和配方方法才能進行局部或全身給藥，而細胞滲透性肽則需要證明細胞攝取和有效載荷相容性。肽激素和胜肽疫苗繼續利用現有的監管途徑，但其穩定性和給藥方案的改進也使其受益，從而擴大了門診給藥的選擇。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 口服胜肽遞送技術的進步提高了病患依從性和市場滲透率
  • 將肽基免疫療法與查核點抑制劑結合以提高癌症治療的療效
  • 自動化胜肽合成平台的出現降低了生產成本並提高了研發的擴充性。
  • 生物活性胜肽營養保健品的採用率不斷提高，以擴大預防保健和健康市場
  • 長效肽類似物進入市場，改變糖尿病管理和患者生活品質
  • 非侵入性胜肽診斷檢測的進展使得早期疾病檢測和即時生物標記監測成為可能
  • 生技公司與CMO之間的策略夥伴關係加速了胜肽療法的生產和商業化
  • 不斷改進監管指導，以解決胜肽生物相似藥問題並促進可互換產品的市場進入
  • 引進人工智慧驅動的序列最佳化平台，更有效率地設計強效穩定的胜肽類候選藥物
  • mRNA-胜肽混合平台的創新推動了感染疾病肽疫苗開發投資的激增

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章胜肽治療市場（依產品類型）

  • 抗菌胜肽
  • 細胞穿透胜肽
  • 肽激素
  • 胜肽疫苗

第9章肽治療市場（按合成技術）

  • 重組胜肽
  • 合成胜肽

第 10 章胜肽治療市場（依給藥途徑）

  • 吸入
  • 注射
    • 肌肉注射
    • 靜脈
    • 皮下
  • 口服
    • 膠囊
    • 液體
    • 藥片
  • 外用
  • 經皮

第11章胜肽治療市場的應用

  • 心血管疾病
    • 心臟衰竭
    • 高血壓
  • 感染疾病
    • 肝炎
    • HIV
    • 流感
  • 代謝紊亂
    • 糖尿病
    • 肥胖
  • 腫瘤學
    • 乳癌
    • 肺癌
    • 黑色素瘤

第 12 章肽治療市場（按最終用戶）

  • 診所
  • 醫院
  • 研究所

第 13 章：胜肽治療市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章胜肽治療市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 15 章 胜肽治療市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Novo Nordisk A/S
    • Eli Lilly and Company
    • Sanofi SA
    • Ferring Pharmaceuticals A/S
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Novartis International AG
    • Takeda Pharmaceutical Company Limited
    • Amgen Inc.
    • Ipsen SA
Product Code: MRR-030EE4851583

The Peptide Therapeutics Market is projected to grow by USD 69.26 billion at a CAGR of 8.61% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 35.76 billion
Estimated Year [2025] USD 38.88 billion
Forecast Year [2032] USD 69.26 billion
CAGR (%) 8.61%

A strategic primer on peptide therapeutics that frames scientific advances, translational enablers, and stakeholder implications for clinical development

Peptide therapeutics have evolved from niche laboratory curiosities into a pivotal modality bridging small molecules and large biologics, reshaping drug discovery and clinical care pathways. Over the past decade, iterative advances in peptide design, stability engineering, and targeted delivery have expanded the therapeutic scope of peptides across metabolic, infectious, cardiovascular, and oncologic indications. This introductory analysis situates peptide therapeutics within the larger biopharmaceutical innovation landscape, emphasizing translational milestones that have unlocked new mechanisms of action and clinical utility.

Translating peptide science into viable therapies has required harmonized progress across chemistry, synthesis techniques, and formulation science. Improvements in solid-phase synthesis, recombinant production, and novel conjugation strategies have increased the chemical diversity and manufacturability of peptide assets. At the same time, regulatory agencies have refined their frameworks for assessing peptide-related quality attributes, which has reduced ambiguity in development pathways and supported more predictable interactions between sponsors and regulators. Consequently, research institutions, small biotechs, and established pharmaceutical companies are increasingly aligning resources to accelerate peptide pipelines.

Looking ahead, the introduction of next-generation stabilization chemistries, enhanced delivery platforms, and computational design tools will continue to lower barriers to clinical translation. As a result, stakeholders must adopt integrated strategies that coordinate discovery, development, and manufacturing to capitalize on the modality's unique therapeutic potential while managing complexity across regulatory, supply chain, and payer landscapes.

How computational design, delivery innovations, and collaborative platform strategies are fundamentally reshaping priorities and pathways in peptide drug development

The contemporary peptide therapeutics landscape is being remade by several transformative shifts that collectively recalibrate research priorities and commercial strategies. First, computational peptide design and AI-enabled sequence optimization have shortened iterative design cycles, enabling teams to prioritize candidates with improved target engagement and pharmacokinetic profiles. Second, breakthroughs in formulation and delivery, including stabilization chemistries and novel excipient systems, have expanded the feasibility of oral and long-acting parenteral peptides, broadening potential patient adherence and outpatient administration.

In parallel, evolving clinical needs are driving diversification of peptide applications. Antimicrobial peptides are being revisited as tools against antimicrobial resistance, while cell penetrating peptides are opening new avenues for intracellular targeting and oligonucleotide delivery. Peptide vaccines are benefiting from improved antigen design and adjuvant systems, positioning them as complementary or alternative approaches to traditional vaccine platforms. These scientific advances are amplified by more fluid collaboration models that bring together academic labs, specialized contract developers, and integrated biopharma teams, thereby accelerating translational momentum.

Concurrently, manufacturing innovations are reshaping production economics and scalability. Recombinant production methods and sequence-optimized synthetic approaches are reducing technical constraints for larger peptides and peptide conjugates. As a result, strategic priorities among developers are shifting from single-asset optimization toward platform capabilities that can support modular pipeline expansion and faster commercialization pathways. Together, these shifts are creating a more dynamic, multidisciplinary ecosystem for peptide therapeutics.

Operational implications of the 2025 United States tariff landscape on peptide supply chains, procurement strategies, and clinical manufacturing continuity

Recent tariff adjustments implemented by the United States in 2025 have introduced a new layer of complexity for peptide supply chains and manufacturing strategies. The cumulative impact extends beyond direct cost implications to influence sourcing decisions, procurement cycles, and geographic allocation of production and quality control activities. Organizations that rely on cross-border raw material procurement, specialized synthesis services, or contract manufacturing relationships have had to re-evaluate their supplier matrices and inventory policies to preserve continuity of clinical and commercial production.

Moreover, the tariff environment has accelerated strategic conversations about localization versus diversification. Some entities are exploring nearer-shoring of critical peptide synthesis and fill/finish capabilities to mitigate exposure to import levies and border-related delays, while others are negotiating longer-term contracts with international suppliers to lock in price stability and access. Legal and compliance teams are simultaneously examining classification codes and supply-chain traceability measures to ensure accurate tariff treatment and to identify potential exemptions where applicable. These operational adjustments have also prompted sponsors to reassess timelines for clinical trial material manufacturing and to integrate tariff risk into procurement governance.

In response, industry participants are adopting mixed mitigation strategies that include dual-sourcing arrangements, onshore capacity investments, and enhanced inventory resilience. As a consequence, development teams are increasingly incorporating tariff scenarios into program risk registers and contingency planning, thereby aligning financial planning with operational realities and preserving patient access commitments while navigating a more fragmented trade landscape.

In-depth segmentation insights showing how product types, synthesis methods, administration routes, therapeutic applications, and end users drive divergent development pathways

Segmentation-driven insights reveal how therapeutic and technical choices influence development priorities and commercial positioning across peptide modalities. Based on product type, developers are differentiating portfolios across antimicrobial peptides, cell-penetrating peptides, peptide hormones, and peptide vaccines, each presenting distinct target validation, safety, and regulatory considerations. Antimicrobial peptides require rigorous resistance profiling and formulation approaches for local or systemic delivery, whereas cell-penetrating peptides demand proof of cellular uptake and payload compatibility. Peptide hormones and peptide vaccines continue to leverage established regulatory pathways but benefit from enhanced stability and delivery solutions that expand outpatient administration options.

Based on synthesis technique, the strategic calculus shifts between recombinant peptides and synthetic peptides, with recombinant methods offering scalability and post-translational mimicry while synthetic approaches provide sequence flexibility and chemical modification opportunities. Development teams must therefore align lead optimization strategies with the chosen production paradigm to ensure downstream manufacturability. Based on route of administration, modality decisions are informed by clinical context: inhalation, injectable, oral, topical, and transdermal pathways each carry different formulation constraints and patient adherence implications. Injectable formats-further delineated into intramuscular, intravenous, and subcutaneous-remain dominant for many biologically active peptides, while oral forms-further categorized into capsule, liquid, and tablet-are becoming feasible for select stabilized sequences.

Based on application, therapeutic focus areas such as cardiovascular diseases, infectious diseases, metabolic disorders, and oncology require tailored translational evidence. Cardiovascular subdomains like heart failure and hypertension pose unique safety and dosing challenges, infectious disease workstreams such as hepatitis, HIV, and influenza emphasize antiviral potency and resistance surveillance, metabolic disorder programs for diabetes and obesity prioritize chronic dosing paradigms and adherence, and oncology indications including breast cancer, lung cancer, and melanoma spotlight targeted delivery and combination strategies. Finally, based on end user, clinics, hospitals, and research institutes exert distinct procurement and implementation pressures that shape positioning, pricing strategies, and evidence generation plans for peptide-based interventions.

How varied regulatory regimes, manufacturing strengths, and clinical priorities across global regions shape distinct strategic imperatives for peptide developers

Regional dynamics in peptide therapeutics reflect differences in regulatory frameworks, clinical priorities, manufacturing ecosystems, and investment flows across major geographies. In the Americas, strong venture capital activity, advanced clinical trial networks, and established biotech hubs continue to fuel early-stage innovation, while regulatory agencies emphasize expedited pathways for high-need indications and structured dialogues for complex biologics. Consequently, sponsors in this region often prioritize rapid clinical proof-of-concept studies and strategic alliances with specialized contract development organizations to translate discoveries into clinic-ready candidates.

Europe, the Middle East & Africa presents a mosaic of regulatory and reimbursement environments with deep academic research capabilities and specialized manufacturing clusters. Cross-border collaborations and consortium-based translational programs are common, supporting peptide vaccine development and infectious disease initiatives where regional public health priorities drive funding and trial recruitment. Here, navigating heterogeneous regulatory expectations and leveraging pan-regional trial networks are key to advancing multi-center programs.

Asia-Pacific combines robust manufacturing scale, rising domestic biopharma talent, and growing healthcare demand, making it a focal point for production capacity and late-stage development activities. Governments across the region continue to invest in biotech infrastructure and manufacturing capability expansion, prompting some organizations to consider Asia-Pacific as a strategic production partner for peptide APIs and formulations. Across all regions, alignment of clinical strategies with local healthcare delivery models and payer expectations remains essential for successful adoption and sustained commercialization.

Analysis of competitive dynamics highlighting how specialized biotechs, platform innovators, and CDMOs shape translational and commercial success in peptide therapeutics

Competitive dynamics in the peptide therapeutics sector are characterized by a layered ecosystem of discovery-focused biotech ventures, platform technology providers, and larger pharmaceutical partners that bring commercialization expertise. Early-stage companies frequently concentrate on niche indications or novel delivery concepts, leveraging specialized scientific expertise and academic collaborations to validate mechanisms of action. At the same time, platform technology firms are investing in modular chemistries, stabilization techniques, and conjugation strategies that can be licensed or partnered to broaden therapeutic reach.

Contract development and manufacturing organizations play a critical role in enabling scale-up and regulatory compliance, offering capabilities that range from research-grade peptide synthesis to GMP production and fill-finish services. These service providers are increasingly differentiating themselves through quality systems, regulatory support offerings, and flexible manufacturing models that accommodate both small-batch clinical material needs and larger commercial volumes. Larger pharmaceutical companies and strategic investors continue to shape the landscape through targeted collaborations, licensing deals, and integration of peptide assets into broader therapeutic portfolios.

Together, these actors create an environment where strategic alignment, intellectual property strategy, and operational excellence determine competitive positioning. Companies that combine robust translational science with clear manufacturing pathways and proactive regulatory engagement are better positioned to move candidates efficiently through development and into clinical practice.

Practical, cross-functional actions that stakeholders should implement now to de-risk pipelines, strengthen supply resiliency, and accelerate clinical translation of peptide innovations

Industry leaders must adopt proactive, integrated strategies to convert scientific advances in peptide therapeutics into durable clinical and commercial outcomes. First, aligning discovery priorities with downstream manufacturing realities is essential; teams should embed manufacturability criteria and regulatory considerations early in the design cycle to reduce technical attrition and accelerate clinical readiness. Establishing cross-functional governance that includes discovery scientists, process development specialists, regulatory leads, and commercial strategists will ensure decisions balance innovation with practical execution.

Second, diversifying supply chains and developing contingency plans for trade and tariff volatility will protect clinical program timelines. Strategic options include dual sourcing of critical raw materials, selective onshoring or nearer-shoring of key production steps, and forging long-term partnerships with trusted contract manufacturers. These measures, combined with enhanced inventory and quality traceability systems, will reduce operational risk and support timely product availability.

Third, invest in platform capabilities that increase program throughput and adaptability. This includes adopting modular synthesis platforms, leveraging in silico design tools to prioritize candidates, and developing flexible formulation approaches that can be adapted across routes of administration. Finally, cultivate collaborative partnerships with academic centers, health systems, and payer stakeholders to co-develop evidence generation plans that demonstrate real-world value and facilitate adoption. Executed together, these actions will strengthen program resilience and maximize the probability of successful translation and market access.

Transparent and reproducible research methods combining expert interviews, literature synthesis, and scenario-based analysis to support strategic decision-making in peptide development

This analysis synthesizes primary and secondary research inputs to present a rigorous view of the peptide therapeutics landscape. Primary research included structured interviews with industry experts, manufacturing and regulatory specialists, and clinical investigators to capture operational experiences and strategic priorities. Secondary sources encompassed peer-reviewed literature, regulatory guidance documents, and public disclosures of development programs to validate scientific trends and regulatory precedents. Data triangulation was used throughout to reconcile divergent perspectives and to ensure conclusions are grounded in multiple lines of evidence.

Analytical processes prioritized transparency and reproducibility. Key themes were identified through coding of qualitative interview data and cross-checked against documented technological advances and regulatory milestones. Where appropriate, scenario analyses were applied to assess operational implications of external factors such as trade policy changes and supply chain disruptions. Limitations of the methodology are acknowledged: insights reflect the viewpoints of interviewed experts and public information available at the time of research, and they do not substitute for bespoke due diligence tailored to specific corporate circumstances.

Nevertheless, by integrating multidisciplinary inputs and applying a consistent analytical framework, the research offers a robust foundation for strategic decision-making. Stakeholders are encouraged to use the methodology notes and expert appendices included with the full report to interpret findings in the context of their own risk tolerance and operational constraints.

Concluding perspective on how integrated technical, regulatory, and operational strategies will determine which peptide initiatives achieve clinical and commercial success

Peptide therapeutics stand at an inflection point driven by converging advances in design, synthesis, and delivery, alongside shifting operational realities in manufacturing and trade. Collectively, these forces are expanding the therapeutic applicability of peptides and compelling organizations to adopt new capabilities in platform development, regulatory navigation, and supply-chain resilience. In this environment, success will depend on the ability to integrate scientific innovation with pragmatic execution strategies that anticipate operational constraints and stakeholder expectations.

As programs move from discovery to clinic, prioritizing manufacturability, regulatory clarity, and evidence generation will reduce technical and commercial risk. Simultaneously, embracing flexible sourcing strategies and strategic partnerships will mitigate exposure to external shocks such as tariff shifts or supply-chain disruptions. Ultimately, organizations that align technical excellence with strategic foresight will be best positioned to translate peptide science into meaningful patient impact and sustainable business models.

The conclusions presented here are intended to guide executives, R&D leaders, and operational managers as they refine portfolios, plan investments, and pursue collaborations. For teams seeking deeper diagnostic analysis or tailored scenario planning, the full report provides expanded evidence, case studies, and operational playbooks to support implementation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in oral peptide delivery technologies enhancing patient compliance and market penetration
  • 5.2. Integration of peptide-based immunotherapies with checkpoint inhibitors to improve cancer treatment efficacy
  • 5.3. Emergence of automated peptide synthesizer platforms reducing production costs and boosting scalability in R&D
  • 5.4. Growing adoption of bioactive peptide nutraceuticals for preventive healthcare and wellness market expansion
  • 5.5. Market entry of long-acting peptide analogues transforming diabetes management and patient quality of life outcomes
  • 5.6. Advances in non-invasive peptide diagnostic assays enabling early disease detection and real-time biomarker monitoring
  • 5.7. Strategic partnerships between biotech firms and CMOs to accelerate peptide therapeutic manufacturing and commercialization
  • 5.8. Regulatory guidances evolving to address peptide biosimilars and facilitate market access of interchangeable products
  • 5.9. Adoption of AI-driven sequence optimization platforms to design potent and stable peptide drug candidates more efficiently
  • 5.10. Investment surge in peptide vaccine development for infectious diseases driven by mRNA-peptide hybrid platform innovations

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Peptide Therapeutics Market, by Product Type

  • 8.1. Antimicrobial Peptides
  • 8.2. Cell Penetrating Peptides
  • 8.3. Peptide Hormones
  • 8.4. Peptide Vaccines

9. Peptide Therapeutics Market, by Synthesis Technique

  • 9.1. Recombinant Peptides
  • 9.2. Synthetic Peptides

10. Peptide Therapeutics Market, by Route Of Administration

  • 10.1. Inhalation
  • 10.2. Injectable
    • 10.2.1. Intramuscular
    • 10.2.2. Intravenous
    • 10.2.3. Subcutaneous
  • 10.3. Oral
    • 10.3.1. Capsule
    • 10.3.2. Liquid
    • 10.3.3. Tablet
  • 10.4. Topical
  • 10.5. Transdermal

11. Peptide Therapeutics Market, by Application

  • 11.1. Cardiovascular Diseases
    • 11.1.1. Heart Failure
    • 11.1.2. Hypertension
  • 11.2. Infectious Diseases
    • 11.2.1. Hepatitis
    • 11.2.2. Hiv
    • 11.2.3. Influenza
  • 11.3. Metabolic Disorders
    • 11.3.1. Diabetes
    • 11.3.2. Obesity
  • 11.4. Oncology
    • 11.4.1. Breast Cancer
    • 11.4.2. Lung Cancer
    • 11.4.3. Melanoma

12. Peptide Therapeutics Market, by End User

  • 12.1. Clinics
  • 12.2. Hospitals
  • 12.3. Research Institutes

13. Peptide Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Peptide Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Peptide Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Novo Nordisk A/S
    • 16.3.2. Eli Lilly and Company
    • 16.3.3. Sanofi S.A.
    • 16.3.4. Ferring Pharmaceuticals A/S
    • 16.3.5. Merck & Co., Inc.
    • 16.3.6. Pfizer Inc.
    • 16.3.7. Novartis International AG
    • 16.3.8. Takeda Pharmaceutical Company Limited
    • 16.3.9. Amgen Inc.
    • 16.3.10. Ipsen S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. PEPTIDE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. PEPTIDE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PEPTIDE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CELL PENETRATING PEPTIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CELL PENETRATING PEPTIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CELL PENETRATING PEPTIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CELL PENETRATING PEPTIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CELL PENETRATING PEPTIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CELL PENETRATING PEPTIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE HORMONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE HORMONES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE HORMONES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE HORMONES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE HORMONES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE HORMONES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY RECOMBINANT PEPTIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY RECOMBINANT PEPTIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY RECOMBINANT PEPTIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY RECOMBINANT PEPTIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY RECOMBINANT PEPTIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY RECOMBINANT PEPTIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHETIC PEPTIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHETIC PEPTIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHETIC PEPTIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHETIC PEPTIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHETIC PEPTIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHETIC PEPTIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LIQUID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LIQUID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LIQUID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LIQUID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LIQUID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HEART FAILURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HEART FAILURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HEART FAILURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HYPERTENSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HYPERTENSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HYPERTENSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HYPERTENSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HYPERTENSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HEPATITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HEPATITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HEPATITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HEPATITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HEPATITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HIV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HIV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HIV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HIV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HIV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HIV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INFLUENZA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INFLUENZA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INFLUENZA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DIABETES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DIABETES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DIABETES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DIABETES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DIABETES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DIABETES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY OBESITY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY OBESITY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY OBESITY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY OBESITY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY OBESITY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY OBESITY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY MELANOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY MELANOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 286. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 292. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 295. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2024 (USD MILLION)
  • TABLE 296. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2025-2032 (USD MILLION)
  • TABLE 297. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 298. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 299. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 300. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 301. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 302. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 303. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 304. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 317. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 318. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 319. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2024 (USD MILLION)
  • TABLE 320. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2025-2032 (USD MILLION)
  • TABLE 321. EUROPE, MIDDLE EAST